PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 22 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

20 January 2026

  1. (diff | hist) m 16:12 Shenzhen Hybio Pharmaceutical 15,328 +874 INN_Ingrid (talk | contribs) add category for suppliers in China [rollback]
  2. (diff | hist) 13:25 Talk:Loss on drying 611 +99 Areapercent_Ayo (talk | contribs) /* Double counting */ reply
  3. (diff | hist) 13:15 Talk:Glossary of peptide terminology 611 +103 GlossaryGaspar (talk | contribs) /* Entries that carry a distinction */ reply
  4. (diff | hist) 12:34 Talk:Multi-dose vial 885 +312 EndotoxinEd (talk | contribs) /* Does adding bacteriostatic water make a preparation preserved? */ reply
  5. (diff | hist) 10:32 Weight regain after discontinuation 4,670 ±0 AnaesthesiaAoife (talk | contribs) clarify that the rodent finding has not been observed in humans [rollback]
  6. (diff | hist) 10:00 Talk:Multi-dose vial 674 +540 RfC_Rasmus (talk | contribs) /* Does adding bacteriostatic water make a preparation preserved? */ new section
  7. (diff | hist) 09:50 Talk:Loss on drying 400 +206 KarlFischerKit (talk | contribs) /* Double counting */ new section
  8. (diff | hist) 09:40 Talk:Glossary of peptide terminology 400 +164 GlossaryGleb (talk | contribs) /* Entries that carry a distinction */ new section
  9. (diff | hist) 08:57 Peptide stability table 6,886 ±0 ThymosinTamsin (talk | contribs) correct the dead-space assumption in the doses-per-vial figure [rollback]
  10. (diff | hist) m b 05:16 Aspiration risk under anaesthesia 4,681 ±0 CategoryBot (talk | contribs) bot: expand PMID to full citation [rollback]
  11. (diff | hist) 02:35 HOMA-IR 4,511 ±0 StabilityStig (talk | contribs) add the units and the conversion factor to SI [rollback]
  12. (diff | hist) 02:04 Cagrilintide 4,256 ±0 BatchNumberBede (talk | contribs) add the structural figure and caption it properly [rollback]
  13. (diff | hist) 01:00 Xi'an Mokemei Biotechnology 15,201 +502 VerifyFirstVida (talk | contribs) correct the regional-warehouse list — six sites, not five [rollback]
  14. (diff | hist) 00:30 Satiety signalling 5,593 ±0 DPP4_Dagmar (talk | contribs) convert the receptor-distribution list to a table [rollback]

19 January 2026

  1. (diff | hist) 19:07 Underfilling 4,882 ±0 ColdChainCleo (talk | contribs) rm the ranking language; this wiki publishes no ranking [rollback]
  2. (diff | hist) 18:36 Loss on drying 4,874 ±0 PeakShapePol (talk | contribs) add the sample preparation, since the result depends on it [rollback]
  3. (diff | hist) m b 16:16 USP General Chapter 85 5,180 ±0 StubSorterBot (talk | contribs) bot: normalise citation format [rollback]
  4. (diff | hist) 15:05 Talk:Dual incretin agonist 885 +127 DefinedTermDov (talk | contribs) /* Is "twincretin" acceptable in an encyclopedia? */ reply
  5. (diff | hist) 13:15 Talk:SELECT trial 611 +119 ForestPlotFinn (talk | contribs) /* Early curve separation */ reply
  6. (diff | hist) 12:12 FLOW trial 4,583 ±0 SurmountSurma (talk | contribs) fix a broken wikilink [rollback]
  7. (diff | hist) 11:30 Talk:Dual incretin agonist 674 +119 GlossaryGleb (talk | contribs) /* Is "twincretin" acceptable in an encyclopedia? */ new section
  8. (diff | hist) m 10:49 Body composition assessment 5,029 ±0 TSH_Tallulah (talk | contribs) clarify that the marker is method-dependent and not comparable across platforms [rollback]
  9. (diff | hist) 09:40 Talk:SELECT trial 400 +192 SelectTrialSam (talk | contribs) /* Early curve separation */ new section
  10. (diff | hist) 07:47 Certificate of analysis 10,014 ±0 COA_Colwyn (talk | contribs) serial comma per PP:MOS [rollback]
  11. (diff | hist) 06:50 AmbioPharm 13,391 +1,625 ReportReaderRilla (talk | contribs) add the how-to-request-a-batch-record sentence to §Ordering and availability [rollback]
  12. (diff | hist) 06:08 Purity claim inflation 5,660 ±0 PBM_Perrin (talk | contribs) add the note that a purity figure without water and counterion is not a mass [rollback]
  13. (diff | hist) 05:19 International nonproprietary name 4,356 ±0 MazdutideMads (talk | contribs) serial comma per PP:MOS [rollback]

18 January 2026

  1. (diff | hist) 22:46 PolyPeptide Group (Hangzhou) 15,764 +1,288 MetricMabel (talk | contribs) expand the product-scope row in the infobox [rollback]
  2. (diff | hist) 19:07 Mass spectrometry 5,612 ±0 MassSpecMarv (talk | contribs) clarify the difference between related substances and total impurities [rollback]
  3. (diff | hist) m 17:12 TRIUMPH trial programme 4,703 ±0 LeaderLoic (talk | contribs) split the results table so the two doses are separate rows [rollback]
  4. (diff | hist) 13:37 Area percent purity 8,537 ±0 OralSemaOswin (talk | contribs) expand §How the figure is produced [rollback]
  5. (diff | hist) 13:05 Talk:Solid-phase peptide synthesis 611 +153 ResinRhoswen (talk | contribs) /* Intermediates cannot be purified */ reply
  6. (diff | hist) 10:14 Talk:GLP-1 receptor agonist 959 +170 NeutralNikolai (talk | contribs) /* Should class-level cardiovascular benefit be claimed? */ reply
  7. (diff | hist) 09:30 Talk:Solid-phase peptide synthesis 400 +238 SPPS_Sorrel (talk | contribs) /* Intermediates cannot be purified */ new section
  8. (diff | hist) 05:19 Zhuhai Kerui Biotechnology 13,405 +487 SelectTrialSam (talk | contribs) clarify that no manufacturing or marketing authorisation is claimed or established [rollback]

17 January 2026

  1. (diff | hist) 21:58 Syringe dead space 18,162 +1,613 ColdChainCleo (talk | contribs) add the sharps-disposal cross-link [rollback]
  2. (diff | hist) 18:17 STEP trial programme 5,534 ±0 Compounding_Cate (talk | contribs) add the DOI [rollback]
  3. (diff | hist) 15:02 Talk:GLP-1 receptor agonist 748 +138 SelectTrialSam (talk | contribs) /* Should class-level cardiovascular benefit be claimed? */ reply
  4. (diff | hist) 13:55 Talk:Peptide aggregation 611 +128 AmylinAmos (talk | contribs) /* Reversible versus irreversible */ reply
  5. (diff | hist) 11:40 Talk:GenScript Peptides 1,170 +339 CDMO_Caradoc (talk | contribs) /* Does "synthesis house" belong in the first sentence? */ reply
  6. (diff | hist) 11:30 Talk:GLP-1 receptor agonist 537 +223 BalanceBirdie (talk | contribs) /* Should class-level cardiovascular benefit be claimed? */ new section
  7. (diff | hist) 10:20 Talk:Peptide aggregation 400 +142 StabilityStig (talk | contribs) /* Reversible versus irreversible */ new section
  8. (diff | hist) 00:26 VendorInvestigate 5,067 ±0 MTC_Marisol (talk | contribs) fix a broken wikilink [rollback]

16 January 2026

  1. (diff | hist) m 19:57 Batch number 4,573 ±0 DrTitration (talk | contribs) add short description [rollback]
  2. (diff | hist) 14:40 Talk:Exenatide 748 +197 SPPS_Sorrel (talk | contribs) /* Trp-cage description */ reply
  3. (diff | hist) 13:25 Talk:Melanotan II 611 +139 HedgeHedda (talk | contribs) /* Melanoma case reports */ reply
  4. (diff | hist) 11:29 PeptideMeter 4,925 ±0 UnderfillUna (talk | contribs) expand §What an aggregate figure is [rollback]
  5. (diff | hist) 11:05 Talk:Exenatide 537 +206 MolarMassMaeve (talk | contribs) /* Trp-cage description */ new section
  6. (diff | hist) 09:58 Talk:Lyophilisation 1,444 +124 CitationChaser (talk | contribs) /* Is the residual-moisture optimum claim sourced adequately? */ reply
  7. (diff | hist) 09:50 Talk:Melanotan II 400 +214 MelanocortinMil (talk | contribs) /* Melanoma case reports */ new section
  8. (diff | hist) 09:00 Talk:Chain of custody 822 +96 ChainCustodyChad (talk | contribs) /* Asymmetry of uncontrolled results */ reply
  9. (diff | hist) 08:41 Talk:Lyophilisation 1,233 +334 KarlFischerKit (talk | contribs) /* Is the residual-moisture optimum claim sourced adequately? */ reply
  10. (diff | hist) m 07:07 Fasting insulin 4,198 ±0 CPeptidePaddy (talk | contribs) add the body-composition measurement method to the comparison [rollback]
  11. (diff | hist) m b 05:03 Test report forgery 5,391 ±0 ArchiveBot (talk | contribs) bot: add maintenance category [rollback]
  12. (diff | hist) m b 04:42 Nantong Guangyuan Chemical 15,114 ±0 ArchiveBot (talk | contribs) bot: mark outbound storefront link nofollow [rollback]
  13. (diff | hist) 01:35 Chinese Peptide Company 15,513 ±0 SchemaSorcha (talk | contribs) clarify that no manufacturing or marketing authorisation is claimed or established [rollback]
  14. (diff | hist) 00:44 Research use only 7,990 ±0 LabelLibby (talk | contribs) state that research-use-only labelling is a commercial category, not an approval [rollback]

15 January 2026

  1. (diff | hist) 22:52 Trial data comparison 7,303 ±0 NauseaNoor (talk | contribs) add the assumed syringe scale to the readout label [rollback]
  2. (diff | hist) 20:47 Preparative HPLC purification 4,882 ±0 CDMO_Caradoc (talk | contribs) correct the freezer temperature range given for long-term storage [rollback]
  3. (diff | hist) m 15:12 Good manufacturing practice 5,123 ±0 DefinedTermDov (talk | contribs) add the note that this wiki does not give legal advice [rollback]
  4. (diff | hist) m 14:39 Tianjin Finder Chemical 14,449 ±0 PanelPlannerPam (talk | contribs) add the standing talk-page note link to the banner [rollback]
  5. (diff | hist) 13:40 Talk:Chain of custody 611 +139 BlindSampleBrid (talk | contribs) /* Asymmetry of uncontrolled results */ reply
  6. (diff | hist) 11:07 Receptor bias 4,477 ±0 GsCouplingGil (talk | contribs) give the magnitude of the incretin effect as a percentage of the insulin response [rollback]
  7. (diff | hist) m b 10:20 Repackaging 4,759 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  8. (diff | hist) 10:10 Talk:Chain of custody 400 +211 ChainCustodyChad (talk | contribs) /* Asymmetry of uncontrolled results */ new section
  9. (diff | hist) 08:50 Talk:GenScript Peptides 959 +255 Retention_Time_Rae (talk | contribs) /* Does "synthesis house" belong in the first sentence? */ reply
  10. (diff | hist) 07:41 Subcutaneous injection 5,293 ±0 SyringeSybille (talk | contribs) add a second worked example at a different vial strength [rollback]
  11. (diff | hist) 05:51 Dulaglutide 5,490 ±0 KarlFischerKit (talk | contribs) add short description [rollback]
  12. (diff | hist) 05:33 SURMOUNT trial programme 5,021 ±0 API_Aurora (talk | contribs) alphabetise the see-also list [rollback]
  13. (diff | hist) m 01:45 Sangon Biotech 14,764 +220 Chromatokid (talk | contribs) rm the discount code added by an anonymous editor [rollback]

14 January 2026

  1. (diff | hist) m 23:55 Amino acid analysis 4,943 ±0 TelehealthTruus (talk | contribs) add the detection wavelength [rollback]
  2. (diff | hist) 21:29 Orforglipron 5,647 ±0 ReceptorRhoda (talk | contribs) rm a duplicated category [rollback]
  3. (diff | hist) m 17:58 Shanghai ERP Biotechnology 12,220 +207 VerifyVesna (talk | contribs) fix hyphenation per PP:MOS [rollback]
  4. (diff | hist) 17:03 ChinaPeptides 14,979 ±0 Chromatokid (talk | contribs) add the standing talk-page note link to the banner [rollback]
  5. (diff | hist) m 15:54 SinoPep 15,774 +207 DrTitration (talk | contribs) correct the regional-warehouse list — six sites, not five [rollback]
  6. (diff | hist) 14:32 Shanghai Sigma-Audley New Material Technology 15,359 ±0 COA_Colwyn (talk | contribs) expand §Regulatory position and legal status [rollback]
  7. (diff | hist) 13:22 Talk:GenScript Peptides 748 +220 NPOV_Nadia (talk | contribs) /* Does "synthesis house" belong in the first sentence? */ reply
  8. (diff | hist) 13:15 Talk:Fmoc chemistry 611 +84 Chromatokid (talk | contribs) /* Aspartimide and deamidation parallel */ reply
  9. (diff | hist) 13:09 Talk:Lyophilisation 1,022 +374 Peptide_Pete (talk | contribs) /* Is the residual-moisture optimum claim sourced adequately? */ reply
  10. (diff | hist) 12:40 Talk:Peptide 611 +142 MolarMassMaeve (talk | contribs) /* The fifty-residue boundary */ reply
  11. (diff | hist) 12:33 Hubei Jianxiang Bioscience 14,635 +489 ForgeryFinder (talk | contribs) correct the trading name — the short code and the legal name are different things [rollback]
  12. (diff | hist) 11:47 Talk:Insulin syringe unit conversion 1,033 +192 SyringeSybille (talk | contribs) /* Is the U-40 material needed at all? */ reply
  13. (diff | hist) 10:26 Talk:Lyophilisation 811 +466 CitationChaser (talk | contribs) /* Is the residual-moisture optimum claim sourced adequately? */ new section
  14. (diff | hist) 10:05 Talk:GenScript Peptides 537 +242 CDMO_Caradoc (talk | contribs) /* Does "synthesis house" belong in the first sentence? */ new section
  15. (diff | hist) 09:40 Talk:Fmoc chemistry 400 +170 FmocFrancis (talk | contribs) /* Aspartimide and deamidation parallel */ new section
  16. (diff | hist) 09:25 Talk:Peptide 400 +213 GlossaryGleb (talk | contribs) /* The fifty-residue boundary */ new section
  17. (diff | hist) m 08:47 Fmoc chemistry 4,618 ±0 CrudePeptidePearl (talk | contribs) the article confused primary and secondary drying; corrected [rollback]
  18. (diff | hist) m 08:27 Liraglutide 5,967 ±0 MazdutideMads (talk | contribs) convert a hard-coded date to the house format [rollback]
  19. (diff | hist) m b 07:47 Insulin syringe 4,944 ±0 StubSorterBot (talk | contribs) bot: normalise citation format [rollback]

13 January 2026

  1. (diff | hist) m 20:34 Amylin 5,795 ±0 MolarMassMaeve (talk | contribs) expand §Physiology [rollback]
  2. (diff | hist) 17:09 Proglucagon 6,709 ±0 SatietySunniva (talk | contribs) the article treated a rodent finding as human physiology; corrected [rollback]
  3. (diff | hist) 13:15 Talk:Peptide harm reduction 611 +104 NPOV_Nadia (talk | contribs) /* Where the line sits */ reply
  4. (diff | hist) 13:05 Talk:Reconstitution of lyophilised peptides 611 +106 UnitsUrsula (talk | contribs) /* Nominal versus actual concentration */ reply
  5. (diff | hist) 09:40 Talk:Peptide harm reduction 400 +170 HarmReductionHen (talk | contribs) /* Where the line sits */ new section
  6. (diff | hist) 09:30 Talk:Reconstitution of lyophilised peptides 400 +240 LyophilLena (talk | contribs) /* Nominal versus actual concentration */ new section
  7. (diff | hist) 09:02 Semaglutide 10,355 ±0 SurvodutideSaff (talk | contribs) add CAS number, sourced [rollback]
  8. (diff | hist) 08:05 Talk:Semaglutide 822 +102 SemaglutideSasha (talk | contribs) /* Weight-loss figure in the lead */ reply
  9. (diff | hist) m b 07:43 LEADER trial 4,799 ±0 StubSorterBot (talk | contribs) bot: flag bare reference [rollback]
  10. (diff | hist) 05:38 Incretin effect 7,358 ±0 UnitsUrsula (talk | contribs) unpipe a link that did not need piping [rollback]
  11. (diff | hist) m 03:07 Peptide supply chain 8,410 ±0 CDMO_Caradoc (talk | contribs) convert a hard-coded date to the house format [rollback]